Navigation Links
Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
Date:2/10/2011

EMERYVILLE, Calif., Feb. 10, 2011 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today articulated for investors the Company's plan of action for 2011 in the development of MF101 (Menerba™). The company also updated its investor information, available on the company's website.

"Having positive clinical and non-clinical data to date, regulatory clarity on requirements from the FDA and the EMA, we can confidently proceed in advancing Menerba into pivotal clinical testing," commented Dr. Isaac Cohen, chairman and chief executive officer of Bionovo, Inc. "Our recent successful financing was an additional validation for Menerba's future development toward commercialization. I look forward to concentrating on executing the business plan and proving the validity of our novel drug development process."

The Company's announced activities and milestones during 2011, based on current plans and progress, include:Manufacture of drug material at higher potency for clinical and non-clinical testing.

  Early first quarter.Conduct a 40 patient, 28-day "tolerability" trial at higher doses planned for later studies.

  Late first quarter, early second quarter.Non-clinical study for toxicity in rodents.

  Late first quarter, early second quarter.Manufacture of clinical material for Phase 3 study, using FDA-approved commercial process.

  Second quarter.Complete contracts, IRB approval and training at U.S. clinical sites for the Phase 3 study.

  First and second quarter.Initiate patient recruitment and screening in the Phase 3 study.

  End of the second quarter.Initiate dosing in the Phase 3 study.

  Early in the third quarter.Data Safety Monitoring Board interim revie
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... July 4, 2015 A global ... hypertension, diabetes and thyroid disorders in Central and ... platforms and a major conference dedicated to these diseases. ... Manage Diabetes Online , Manage Hypertension Online ... and operated by EXCEMED - combine the ...
(Date:7/3/2015)... -- Obsidian HDS, the developer of PharmaShine ( www.pharmashine.com ... of data on pharmaceutical and device industry payments to ... 2014 Open Payments General and Research data released by ... data disclosed on Open Payments for 2014 includes information ... $6.49 billion and is the largest public disclosure of ...
(Date:7/2/2015)... , July 2, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... shares have been approved for listing and trading on the ... ESSA will begin trading on NASDAQ on July 9, 2015.  ... Exchange under the symbol "EPI". As a result ... each of the Company,s outstanding special warrants issued on January ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4
... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... emerging leader in the development, assembly, marketing and sale ... today announced that it was granted three new patents ... of China ("SIPO"). The patent awards were related to ...
... Cellular Dynamics International (CDI) today announced the online publication ... demonstrating for the first time a methodology for researchers ... blood samples through the creation of induced pluripotent stem ... B-cell lines reprogrammed to EBV-free induced pluripotent stem cells," ...
Cached Medicine Technology:Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2
(Date:7/5/2015)... ... July 05, 2015 , ... Doctors at the Swedish Cancer ... combination may one day change the outlook for people with pleural mesothelioma. Surviving Mesothelioma ... , Researchers report that five mesothelioma patients treated with 25Gy of radiation over ...
(Date:7/4/2015)... New York, NY (PRWEB) , ... July 04, 2015 , ... ... suggest that 15% of chronic pain sufferers have pain located in the neck. Another ... referred from the neck. Chiropractic literature suggests that 45% of American workers ...
(Date:7/3/2015)... ... July 04, 2015 , ... The Harvest Hope Food Bank will hopefully be ... AlignLife offices in the area of Greenville SC are making it their mission ... by patients only. They are asking for donations from the public as well. As part ...
(Date:7/3/2015)... , ... July 03, 2015 ... ... the sessions and speaker lineup for its 2015 Annual Conference , ... August 6-8, 2015 at the Renaissance Orlando at SeaWorld in Orlando, Florida. ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national president recruitment for Regional ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3
... Dec. 8 BHR Pharma, LLC (BHR) ... application with the U.S. Food and Drug Administration (FDA) for its ... year, the company made public plans to initiate a global, Phase ... the safety and effectiveness of BHR-100 as a neuroprotective agent for ...
... , CINCINNATI and JACKSONVILLE, Fla., Dec. 8 LCA-Vision ... correction services under the Lasik Plus ® brand, announced today that ... free Lasik Plus® corrective vision surgery to U.S. military veterans ... Warrior Project, and is doing its part to enhance the lives ...
... , SAN DIEGO, Dec. 8 PROVERI, Inc. ... a winner of the annual New England Venture Summit Top Innovator ... recognizes those that play a leading role in innovation for the ... winners, Waldemar Lernhardt, Ph.D., President and Chief Executive Officer of PROVERI, ...
... , ANN ARBOR, Mich., Dec. 8 ... bench-top flow cytometer systems, today announced the 2009 recipients of ... free Accuri C6 Flow Cytometer® System each year to two ... Europe, who propose innovative uses of flow cytometry. Explicitly ...
... , LONDON, ... both structural reform and unavailability of resources as the region,s working ... This calls for the introduction of new schemes in healthcare that ... ageing population. The involvement of Information and Communication Technology (ICT) in ...
... ... UK’s premier centre for Integrated Medicine, launches Regenerus, the most comprehensive anti-ageing assessment and ... ... Secretary, Andy Burnham, published the results of a Department of Health Survey that reveals ...
Cached Medicine News:Health News:BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment 2Health News:LCA-Vision Joins Forces With the Wounded Warrior Project to Give the Gift of Enhanced Vision to Wounded American Heroes 2Health News:PROVERI, Inc. Named a Top Innovator Winner 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 3Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 4Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
The Uro San® Plus male external catheter is a latex catheter with a double-sided adhesive and Shield Skin Protective Dressing....
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products: